Achieve Life Sciences, Inc.
NASDAQ:ACHVBiotechnology
-$0.38 today
- Market cap
- $697.68M
- Beta
- 2.26
- P/E (TTM)
- -5.1
- EPS (TTM)
- -$0.97
Volume 1.09M
Average 1.44M
Returns on capital
Achieve Life Sciences, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-254.0%
avg 44.6%
ROIC
-150.5%
avg -101.8%
ROA
-130.8%
avg -89.9%
Analysis
ROA is currently the strongest return metric at -130.8% versus its period average of -89.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Erik Atkisson | Chief Legal Officer | USD 521.02K | 54 | 250.00K | 0.24% |
Benjamin Halladay | Chief Financial Officer | USD 425.24K | 40 | 0 | <0.01% |
Mark K. Oki | Chief Financial Officer | USD 425.24K | 57 | 180.00K | 0.18% |
Andrew D. Goldberg | CEO, President & Director | — | 44 | 0 | <0.01% |
Mark L. Rubinstein | Chief Medical Officer | — | 58 | — | — |
Gloria Cosgrove | Senior Vice President of Global Quality | — | — | — | — |
Kaitlyn Tuson | Senior Vice President of Marketing & Communications | — | — | — | — |
Ronald Dadino | Senior Vice President of Chemistry, Manufacturing & Controls and Supply Chain | — | — | — | — |
Jerry Wan | Vice President of Finance & Principal Accounting Officer | — | 44 | 70.30K | 0.07% |
Mark Zappia | Senior Vice President of Commercial | — | — | — | — |
Nicole Jones | Vice President of Strategic Communications & Stakeholder Relations | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 5, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
1
$175,176.62
Net Transaction Value
−$175,176.62
Net selling
Most Active
Stewart Richard Alistair
1 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Aug 19, 26Aug 19, 2026 | Stewart Richard Alistair Direct | Sell | $175.2K$175,176.62 |
Summary
Insiders reported 0 buys worth $0.00 and 1 sells worth $175,176.62 over the last 12 months. That adds up to net selling of $175,176.62. Stewart Richard Alistair was the most active insider with 1 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Achieve Life Sciences, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
No competitor data available.
Questions
Management questions
Common questions about ACHV's management, answered from reported figures.
Who manages ACHV?
Achieve Life Sciences, Inc. (ACHV) lists 11 active executives. The top listed executive is Andrew D. Goldberg, CEO, President & Director.
Are ACHV insiders buying or selling?
Recent insider activity shows net buying of $30.49M.
Continue the stock analysis
Jump to another research area for this company.